[go: up one dir, main page]

PE20091821A1 - Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada - Google Patents

Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada

Info

Publication number
PE20091821A1
PE20091821A1 PE2009000437A PE2009000437A PE20091821A1 PE 20091821 A1 PE20091821 A1 PE 20091821A1 PE 2009000437 A PE2009000437 A PE 2009000437A PE 2009000437 A PE2009000437 A PE 2009000437A PE 20091821 A1 PE20091821 A1 PE 20091821A1
Authority
PE
Peru
Prior art keywords
antibody
type
ccda
antibodies
combination therapy
Prior art date
Application number
PE2009000437A
Other languages
English (en)
Inventor
Charles Dumontet
Thomas Friess
Christian Klein
Fernandez Pablo Umana
Original Assignee
Hoffmann La Roche
Glycart Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091821(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche, Glycart Biotechnology Ag filed Critical Hoffmann La Roche
Publication of PE20091821A1 publication Critical patent/PE20091821A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE CONTIENE: A) UN ANTICUERPO CD20 TIPO II TAL COMO B-Ly1 GLUCO-MODIFICADO HUMANIZADO, CON CITOTOXICIDAD DEPENDIENTE DE ANTICUERPOS AUMENTADA; B) UNO O MAS AGENTES QUIMIOTERAPEUTICOS TALES COMO CICLOFOSFAMIDA, VINCRISTINA O DOXORRUBICINA. DICHA COMPOSICION ES UNA COMBINACION UTIL EN EL TRATAMIENTO DEL CANCER QUE EXPRESA CD20, EN PARTICULAR EN LINFOMAS DE CELULAS B NO HODGKIN (LNH)
PE2009000437A 2008-03-25 2009-03-24 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada PE20091821A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08005554 2008-03-25
EP08007172 2008-04-11

Publications (1)

Publication Number Publication Date
PE20091821A1 true PE20091821A1 (es) 2009-11-25

Family

ID=40872445

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000437A PE20091821A1 (es) 2008-03-25 2009-03-24 Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada

Country Status (31)

Country Link
US (6) US20090246197A1 (es)
EP (1) EP2268310B1 (es)
JP (3) JP5547709B2 (es)
KR (1) KR101280716B1 (es)
CN (2) CN107198772A (es)
AR (1) AR072947A1 (es)
AU (1) AU2009228616B2 (es)
BR (1) BRPI0909227B8 (es)
CA (1) CA2716884C (es)
CL (1) CL2009000713A1 (es)
CR (1) CR11687A (es)
CY (1) CY1117984T1 (es)
DK (1) DK2268310T3 (es)
ES (1) ES2592312T3 (es)
HR (1) HRP20161301T1 (es)
HU (1) HUE028828T2 (es)
IL (1) IL208018A (es)
LT (1) LT2268310T (es)
MA (1) MA32140B1 (es)
MX (1) MX2010009647A (es)
MY (1) MY163544A (es)
NZ (1) NZ587284A (es)
PE (1) PE20091821A1 (es)
PL (1) PL2268310T3 (es)
PT (1) PT2268310T (es)
RS (1) RS55258B1 (es)
RU (1) RU2589704C2 (es)
SI (1) SI2268310T1 (es)
TW (1) TWI500624B (es)
WO (1) WO2009118142A1 (es)
ZA (1) ZA201006190B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961563B2 (ja) 1991-01-29 1999-10-12 株式会社トーキン パルス発生用磁気ワイヤの製造方法
KR101364902B1 (ko) 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
PT2268310T (pt) * 2008-03-25 2016-08-23 Roche Glycart Ag Uso de um anticorpo anti-cd20 do tipo ii com citotoxicidade celular acrescida dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não-hodgkin
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20120087915A1 (en) 2010-06-03 2012-04-12 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
EP2651976A1 (en) * 2010-12-16 2013-10-23 Roche Glycart AG Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
IL317457A (en) * 2011-10-19 2025-02-01 Pharmacyclics Llc Use of Bruton's tyrosine kinase inhibitors
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
JP2017501157A (ja) * 2013-12-17 2017-01-12 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｃｄ２０抗体を使用してがんを治療する方法
US9603927B2 (en) * 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA122212C2 (uk) 2014-09-09 2020-10-12 Янссен Байотек, Інк. Вид комбінованої терапії з застосуванням антитіла до cd38
IL307913A (en) 2014-12-04 2023-12-01 Janssen Biotech Inc Anti-CD38 antibodies for the treatment of acute myeloid leukemia
AU2016245958B2 (en) 2015-04-08 2021-09-09 Novartis Ag CD20 therapies, CD22 therapies, and combination therapies with a CD19 Chimeric Antigen Receptor (CAR) - expressing cell
MY198983A (en) 2015-05-20 2023-10-06 Janssen Biotech Inc Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
WO2016209921A1 (en) 2015-06-22 2016-12-29 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
SG11201803678SA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
TW201733621A (zh) * 2015-12-10 2017-10-01 世代好公司 細胞穿透性之花青耦合抗體
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
EP4108183A1 (en) 2017-03-30 2022-12-28 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP2021502961A (ja) 2017-10-31 2021-02-04 ヤンセン バイオテツク，インコーポレーテツド 高リスク多発性骨髄腫の治療方法
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
EP3883636A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
KR20220079858A (ko) * 2019-10-04 2022-06-14 추가이 세이야쿠 가부시키가이샤 오비누투주맙 내성 cd20 양성 암의 세포의 증식을 억제하는 제, 및 그에 관련된 의약 조성물, 의약, 제조, 세포의 증식을 억제하는 방법, 치료 방법, ii형 항cd20 항체, 화합물, 그들의 조합, 증강제 및 유도제
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5736137A (en) * 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US6602684B1 (en) * 1998-04-20 2003-08-05 Glycart Biotechnology Ag Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
RU2306952C2 (ru) * 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
SI1558648T1 (sl) * 2002-10-17 2012-05-31 Genmab As Človeška monoklonalna protitelesa proti CD
EP1572744B1 (en) * 2002-12-16 2010-06-09 Genentech, Inc. Immunoglobulin variants and uses thereof
KR101364902B1 (ko) * 2003-11-05 2014-02-21 로슈 글리카트 아게 증가된 ｆｃ 수용체 결합 친화성 및 효과기 기능을 가진 ｃｄ20 항체
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
EP1891113A2 (en) * 2005-06-02 2008-02-27 AstraZeneca AB Antibodies directed to cd20 and uses thereof
JP5373396B2 (ja) * 2005-08-26 2013-12-18 ロシュ グリクアート アクチェンゲゼルシャフト 改変された細胞シグナル活性有する改変抗原結合分子
KR101234436B1 (ko) * 2007-09-05 2013-02-18 로슈 글리카트 아게 유형 ⅰ 및 유형 ⅱ 항-ｃｄ２０ 항체를 사용하는 병용 치료요법
PT2268310T (pt) * 2008-03-25 2016-08-23 Roche Glycart Ag Uso de um anticorpo anti-cd20 do tipo ii com citotoxicidade celular acrescida dependente de anticorpo (adcc) em combinação com ciclofosfamida, vincristina e doxorubicina para tratar linfomas não-hodgkin

Also Published As

Publication number Publication date
KR20100121525A (ko) 2010-11-17
TW200951141A (en) 2009-12-16
AU2009228616A1 (en) 2009-10-01
US20140065134A1 (en) 2014-03-06
CL2009000713A1 (es) 2010-04-09
MX2010009647A (es) 2010-09-28
CA2716884A1 (en) 2009-10-01
WO2009118142A1 (en) 2009-10-01
CA2716884C (en) 2017-10-03
EP2268310A1 (en) 2011-01-05
KR101280716B1 (ko) 2013-07-01
ES2592312T3 (es) 2016-11-29
IL208018A (en) 2017-12-31
IL208018A0 (en) 2010-12-30
US20160000911A1 (en) 2016-01-07
DK2268310T3 (en) 2016-08-15
AU2009228616B2 (en) 2014-07-24
RU2010143454A (ru) 2012-05-10
US20100310581A1 (en) 2010-12-09
HRP20161301T1 (hr) 2016-11-18
JP2014101370A (ja) 2014-06-05
ZA201006190B (en) 2018-11-28
HUE028828T2 (en) 2017-01-30
TWI500624B (zh) 2015-09-21
CR11687A (es) 2011-01-10
CN107198772A (zh) 2017-09-26
US20090246197A1 (en) 2009-10-01
SI2268310T1 (sl) 2016-11-30
JP2011515428A (ja) 2011-05-19
LT2268310T (lt) 2016-09-26
RS55258B1 (sr) 2017-02-28
BRPI0909227B8 (pt) 2021-05-25
CY1117984T1 (el) 2017-05-17
PT2268310T (pt) 2016-08-23
JP5547709B2 (ja) 2014-07-16
US20110177067A1 (en) 2011-07-21
AR072947A1 (es) 2010-10-06
BRPI0909227A2 (pt) 2015-12-01
BRPI0909227B1 (pt) 2020-11-24
RU2589704C2 (ru) 2016-07-10
JP2016121183A (ja) 2016-07-07
MY163544A (en) 2017-09-29
US20120301459A1 (en) 2012-11-29
JP6154039B2 (ja) 2017-06-28
PL2268310T3 (pl) 2017-08-31
NZ587284A (en) 2012-05-25
EP2268310B1 (en) 2016-07-20
JP5912142B2 (ja) 2016-04-27
CN101983071A (zh) 2011-03-02
MA32140B1 (fr) 2011-03-01

Similar Documents

Publication Publication Date Title
PE20091821A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente de anticuerpos (ccda) aumentada
AR068818A1 (es) Terapia de combinacion con anticuerpos anti-cd20, de tipo i y de tipo ii para el tratamiento del cancer , uso, kit
PE20090975A1 (es) Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un inhibidor de proteasoma
AR077866A1 (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina
NI200900022A (es) Anticuerpo especifico de prlr y usos del mismo
CL2011001256A1 (es) Combinacion farmaceutica que comprende a un anticuerpo que reconoce especificamente a cd38, y ciclofosfamida, donde dicho anticuerpo es capaz de eliminar una celula cd38+ por apoptosis, citotoxicidad mediada por celulas dependiente de anticuerpo (adcc), y citotoxicidad dependiente de complemento (cdc).
PE20170903A1 (es) Conjugados de farmacos con anticuerpos anti-cdh6
CL2012002012A1 (es) Anticuerpo anti-cd38 o fragmento de este, capaz de destruir una célula cd38+ por apoptosis, citotoxicidad celular adcc y citotoxicidad cdc; anticuerpo humanizado; polinucleótido, vector y célula huésped que lo codifican; conjugado del anticuerpo con un compuesto citotóxico; composición farmacéutica con dichos anticuerpos; uso de los anticuerpos para tratar cáncer o enfermedad autoinmune; método para diagnosticar cáncer.
AR074220A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y vincristina y uso
CL2012000921A1 (es) Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes.
PH12012500870A1 (en) Spiro-oxindole mdm2 antagonists
PE20120902A1 (es) Anticuerpos anti-egfl7 humanizados
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
CR20110553A (es) Terapia complementaria contra el cáncer
DOP2013000260A (es) Uso del anticuerpo anti-cd19 inmunoconjugado con maitansinoide para el tratamiento del síntoma tumores de células b
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
CL2008003846A1 (es) Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata.
CL2008000670A1 (es) Compuestos derivados de tiazolidindionas y oxazolidindionas sustituidas; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamiento de enfermedades tales como artritis reumatoide, epoc, cancer, entre otras.
MX339006B (es) Metodos para convertir material lignocelulosico en productos utiles.
CL2012001405A1 (es) Compuestos derivados de espiroindolinona-pirrolidinas; proceso de obtención; composicion farmaceutica; y uso en el tratamiento o profilaxis del cancer.
CL2013003570A1 (es) Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio.
GEP20186816B (en) Anty il-36r antybodies
MY170932A (en) Saponin-containing, beer-taste beverages
CL2008001213A1 (es) Uso de compuestos derivados de piridin-4-il-benceno-1,4-diamino sustituidos por alquindol para preparar un medicamento para el tratamiento de un trastorno proliferativo tal como el cancer.
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal